Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 98. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Navigating the complexity: reflections on the development of perioperative cancer treatments655
Dual therapy in metastatic castration-resistant prostate cancer596
US FDA proposes stronger laboratory test oversight533
Enhancing equity and long-term impact assessments in radiotherapy environmental studies479
Palliative radiotherapy for hepatic cancer pain464
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply462
SANO trial: innovations, risks, and unanswered questions405
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia399
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study398
Toxicity assessment bias in the PACE-C trial – Authors' reply393
New national cancer registry for France379
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX348
The future of precise cancer chronotherapeutics343
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply319
Olanzapine for chemotherapy-induced nausea and vomiting control300
Study bolsters concerns about US FDA accelerated drug approvals290
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply288
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy285
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer283
Combination immunotherapy in chemotherapy in gastric cancer271
Patients with cancer in Louisiana denied fertility preservation cover260
Use of artificial intelligence to enhance detection of nodal metastases260
The GLOW trial in chronic lymphocytic leukaemia254
Precision medicine for children with cancer251
Concern for cancer drugs in USA–EU tariff war249
IVLBCL mimicking VEXAS syndrome249
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation249
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies246
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer243
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial233
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment221
US Surgeon General calls for cancer warning labels on alcohol219
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges218
Correction to Lancet Oncol 2022; 23: 1124–26218
The silent malignant mesothelioma epidemic: a call to action216
Determining the optimal use of approved drugs in oncology207
ALND after neoadjuvant chemotherapy: a call for caution204
Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer199
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries197
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial196
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t189
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas188
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o187
A new generation of comprehensive precision oncology trials180
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis178
Clinical benefit and the Trump administration's cancer medicine reforms178
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm176
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers169
Italy to pass law on the right to be forgotten for cancer survivors169
Correction to Lancet Oncol 2021; 22: 1081–92166
Antibody–drug conjugates in acute myeloid leukaemia: more research needed166
Health insurance system in Japan faces risk of politicisation165
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus165
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospec164
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 164
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 155
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi149
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial145
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study145
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial144
Innovation in gynaecological cancer: highlighting global disparities144
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult139
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer138
Mantle cell lymphoma: is it time for risk-adapted treatment?138
Cancer on the agenda during IAEA Director General's visit to Chile137
Lung cancer rates highest among British Bangladeshi men136
Balancing clinical benefit and social value: challenges in HTA assessments135
Daratumumab maintenance in patients with myeloma133
Challenges and prospects for cancer treatment in prison settings132
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:131
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update127
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study124
Clearing the radiotherapy backlog: innovation to pave the way123
Common Sense Oncology: including everyone120
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer119
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?118
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study116
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer116
Importance of clinical research for the UK's 10-year cancer plan116
Essential anticancer medicines for children: defining what matters most for Europe115
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo114
Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer114
The power of words: evaluating the role of qualitative methods in cancer research112
Decentralised, point-of-care CAR-T for multiple myeloma111
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial111
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit106
Oral contraceptives and risk of liver cancer106
WHO reports health service disruptions due to suspensions of aid105
Systemic therapy for brain metastases: a changing landscape104
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply104
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer103
ESMO Congress 2025103
India rolls out HPV vaccination102
Antimicrobial resistance in patients with haematological malignancies: a scoping review102
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK99
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire99
Canada's Yukon Territory publishes First Nations Cancer Strategy99
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials98
0.30316090583801